In a unique collaboration Maersk and Covid-19 vaccine developer COVAXX say they intend to “democratise health worldwide,” through an agreement to distribute the medical company’s new vaccine around the globe.
The COVAXX vaccine, UB-612, is still undergoing tests in Taiwan and, but the company expects that once testing is completed up to a billion doses of the vaccine will need to be distributed to communities around the world.
COVAXX’s UB-612 vaccine, which is designed to mimic human immune systems, is currently undergoing phase 1 clinical trials in Taiwan, but there is, “An agreement with the University of Nebraska Medical Center to conduct Phase 2 trials in the United States, upon regulatory approval.”
Moreover, the company has advanced orders for over 100 million doses of UB-612. “In September, COVAXX announced an agreement with Dasa, the largest diagnostic medical company in Brazil to conduct a large-scale human efficacy clinical trial in Brazil.”
“The COVAXX vaccine is unique in that it can be stored in the fridge you have at home, moved in the same trucks that deliver groceries and administered anywhere you can get a flu shot.” said Lou Reese co-CEO at COVAXX.
It is the comparatively simple ability to transport the vaccine that makes COVAXX’s mission to defeat Covid-19 and “ultimately democratise health worldwide,” considerably more achievable. Maersk’s task, within this objective, is to help fulfil that mission by overseeing all the logistics and distribution services that will “ensure efficient transportation to developing countries.”
“Efficient and safe delivery of Covid-19 vaccines around the world is the most urgent logistics challenge we face today. AP Moller – Maersk is committed to working closely with COVAXX to ensure smooth end-to-end global delivery of this vaccine as soon as it becomes available,” said Rob Townley, head of special project logistics at Maersk. “Our specialised logistics expertise and the global infrastructure of Maersk make this a perfect match.”